<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DDAVP  RHINAL TUBE- desmopressin acetate solution </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<h1>DDAVP<span class="Sup">®</span><br>Rhinal Tube<br>(desmopressin acetate)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">DDAVP<span class="Sup">®</span> Rhinal Tube</span> (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows:</p>
<p>Mol. wt. 1183.34              Empirical formula: C<span class="Sub">46</span>H<span class="Sub">64</span>N<span class="Sub">14</span>O<span class="Sub">12</span>S<span class="Sub">2</span>•C<span class="Sub">2</span>H<span class="Sub">4</span>O<span class="Sub">2</span>•3H<span class="Sub">2</span>O</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-01.jpg"></div>
<p>1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate.</p>
<p><span class="Bold">DDAVP Rhinal Tube</span> is provided as an aqueous solution for intranasal use.</p>
<p>Each mL contains:</p>
<table width="60%">
<col align="left" width="50%">
<col align="left" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left">Desmopressin acetate</td>
<td align="left">0.1 mg</td>
</tr>
<tr>
<td align="left">Chlorobutanol</td>
<td align="left">5.0 mg</td>
</tr>
<tr>
<td align="left">Sodium Chloride</td>
<td align="left">9.0 mg</td>
</tr>
<tr class="Last"><td align="left" colspan="2">Hydrochloric acid to adjust pH to approximately 4</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="Bold">DDAVP Rhinal Tube</span> contains as active substance desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (0.1 mg) of intranasal DDAVP (desmopressin acetate) has an antidiuretic activity of about 400 IU; 10 mcg of desmopressin acetate is equivalent to 40 IU.</p>
<ol>
<li>The biphasic half-lives for intranasal DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone used in this condition. As a result, intranasal DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration.</li>
<li>The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.</li>
<li>DDAVP administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection.</li>
</ol>
<div class="Section" data-sectionCode="42229-5">
<a name="clinical_pharmacology_human"></a><a name="section-2.1"></a><p></p>
<h2>Human Pharmacokinetics</h2>
<p class="First">DDAVP is mainly excreted in the urine. A pharmacokinetic study conducted in healthy volunteers and patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (n=24, 6 subjects in each group) receiving single dose desmopressin acetate (2mcg) injection demonstrated a difference in DDAVP terminal half-life. Terminal half-life significantly increased from 3 hours in normal healthy patients to 9 hours in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Central Cranial <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First"><span class="Bold">DDAVP Rhinal Tube</span> is indicated as antidiuretic replacement therapy in the management of central cranial <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> and for management of the temporary <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> following head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or surgery in the pituitary region. It is ineffective for the treatment of <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>.</p>
<p>The use of <span class="Bold">DDAVP Rhinal Tube</span> in patients with an established diagnosis will result in a reduction in urinary output with increase in urine <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> and a decrease in plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>. This will allow the resumption of a more normal life-style with a decrease in <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>.</p>
<p>There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.</p>
<p>Patients are selected for therapy by establishing the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued response to intranasal DDAVP can be monitored by urine volume and <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>.</p>
<p>DDAVP is also available as a solution for injection when the intranasal route may be compromised. These situations include <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> and blockage, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">nasal discharge</span>, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of nasal mucosa, and severe atrophic <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">DDAVP Rhinal Tube</span> is contraindicated in individuals with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to desmopressin acetate or to any of the components of <span class="Bold">DDAVP Rhinal Tube</span>.</p>
<p>DDAVP is contraindicated in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined as a creatinine clearance below 50ml/min).</p>
<p>DDAVP is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> or a history of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<ol>
<li>For intranasal use only.</li>
<li>
<span class="Bold">DDAVP Rhinal Tube</span> should only be used in patients where orally administered formulations are not feasible.</li>
<li>Very rare cases of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> have been reported from world-wide postmarketing experience in patients treated with DDAVP (desmopressin acetate). DDAVP is a potent antidiuretic which, when administered, may lead to <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. Unless properly diagnosed and treated <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> can be fatal. Therefore, fluid restriction is recommended and should be discussed with the patient and/or guardian. Careful medical supervision is required.</li>
<li>When DDAVP is administered, in particular, in pediatric and geriatric patients, fluid intake should be adjusted downward in order to decrease the potential occurrence of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. (See <span class="Bold"><a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#precautions_geriatric">Geriatric Use</a></span>.) All patients receiving DDAVP therapy should be observed for the following signs or symptoms associated with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>:  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, decreased serum sodium, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, depressed reflexes, loss of appetite, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> and abnormal mental status such as <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, decreased consciousness and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. Severe symptoms may include one or a combination of the following: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and/or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>. Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> that may result in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> which could lead to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</li>
<li>DDAVP should be used with caution in patients with habitual or <span class="product-label-link" type="condition" conceptid="4049477" conceptname="Psychogenic polydipsia">psychogenic polydipsia</span> who may be more likely to drink excessive amounts of water, putting them at greater risk of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Intranasal DDAVP at high dosage has infrequently produced a slight elevation of blood pressure, which disappeared with a reduction in dosage. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease because of possible <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>.</p>
<p>DDAVP should be used with caution in patients with conditions associated with fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, such as <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disorders</span> because these patients are prone to <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold">Ensure that in children administration is under adult supervision in order to control the dose intake.</span></p>
<p>Rare severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported with DDAVP. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported rarely with intravenous and intranasal administration of DDAVP.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Central Cranial <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First">Since <span class="Bold">DDAVP Rhinal Tube</span> is used intranasally, changes in the nasal mucosa such as <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, or other disease may cause erratic, unreliable absorption in which case intranasal DDAVP should not be used. For such situations, DDAVP Injection should be considered.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Laboratory tests for following the patient with central cranial <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> or post-surgical or head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>-related <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span> include urine volume and <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>. In some cases plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> measurements may be required.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Although the pressor activity of DDAVP is very low compared to the antidiuretic activity, use of large doses of intranasal DDAVP with other pressor agents should only be done with careful patient monitoring. The concomitant administration of drugs that may increase the risk of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine and carbamazepine) should be performed with caution.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.6"></a><p></p>
<h2>Pregnancy Category B</h2>
<p class="First">Fertility studies have not been done. Teratology studies in rats and rabbits at doses from 0.05 to 10 mcg/kg/day (approximately 0.1 times the maximum systemic human exposure in rats and up to 38 times the maximum systemic human exposure in rabbits based on surface area, mg/m<span class="Sup">2</span>) revealed no harm to the fetus due to DDAVP. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Several publications of desmopressin acetate's use in the management of <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> during pregnancy are available; these include a few anecdotal reports of congenital anomalies and low birth weight babies. However, no causal connection between these events and desmopressin acetate has been established. A fifteen year, Swedish epidemiologic study of the use of desmopressin acetate in pregnant women with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> found the rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> to be no greater than that in the general population; however the statistical power of this study is low. As opposed to preparations containing natural hormones, desmopressin acetate in antidiuretic doses has no uterotonic action and the physician will have to weigh the therapeutic advantages against the possible risks in each case.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP (desmopressin acetate) in breast milk following an intranasal dose of 10 mcg. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DDAVP is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Pediatric_Use"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.8.1"></a><p></p>
<h3>Central Cranial <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h3>
<p class="First"><span class="Bold">DDAVP Rhinal Tube</span> has been used in pediatric patients with <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span>. Use in infants and pediatric patients will require careful fluid intake restriction to prevent possible <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>. Fluid restriction should be discussed with the patient and/or guardian. (See <span class="Bold"><a href="#warnings">WARNINGS</a></span>.) The dose must be individually adjusted to the patient with attention in the very young to the danger of an extreme decrease in plasma <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> with resulting <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Dose should start at 0.05 mL or less.</p>
<p>There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="precautions_geriatric"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of DDAVP Rhinal Tube did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. DDAVP is contraindicated in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (defined as a creatinine clearance below 50ml/min). </p>
<p>(See <span class="Bold"><a href="#clinical_pharmacology_human">CLINICAL PHARMACOLOGY, Human Pharmacokinetics</a></span> and <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>.)</p>
<p>Use of DDAVP Rhinal Tube in geriatric patients will require careful fluid intake restrictions to prevent possible <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>. Fluid restriction should be discussed with the patient. (See <span class="Bold"><a href="#warnings">WARNINGS</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse_reactions"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Infrequently, high dosages of intranasal DDAVP have produced transient <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> have also been reported occasionally along with mild <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. These symptoms disappeared with reduction in dosage. <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Nosebleed</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span> have also been reported.</p>
<p>The following table lists the percent of patients having adverse experiences without regard to relationship to study drug from the pooled pivotal study data for <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">nocturnal enuresis</span>.</p>
<table width="100%">
<col align="left" width="30%">
<col align="center" width="23%">
<col align="center" width="22%">
<col align="center" width="25%">
<thead>
<tr class="First">
<th align="left">  </th>
<th align="center" valign="bottom">PLACEBO<br><span class="Underline">(N=59)</span>
</th>
<th align="center" valign="bottom">DDAVP<br>20 mcg<br><span class="Underline">(N=60)</span>
</th>
<th align="center" valign="bottom">DDAVP<br>40 mcg<br><span class="Underline">(N=61)</span>
</th>
</tr>
<tr class="Last">
<th align="left"><span class="Underline">ADVERSE REACTION</span></th>
<th align="center">%</th>
<th align="center">%</th>
<th align="center">%</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">BODY AS A WHOLE</td>
<td align="center">  </td>
<td align="center">  </td>
<td align="center">  </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">NERVOUS SYSTEM</td>
<td align="center">  </td>
<td align="center">  </td>
<td align="center">  </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">RESPIRATORY SYSTEM</td>
<td align="center">  </td>
<td align="center">  </td>
<td align="center">  </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  Nostril <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center">2</td>
<td align="center">8</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">DIGESTIVE SYSTEM</td>
<td align="center">  </td>
<td align="center">  </td>
<td align="center">  </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorder</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">SPECIAL SENSES</td>
<td align="center">  </td>
<td align="center">  </td>
<td align="center">  </td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> Eyes</td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td align="left">  Lachrymation Disorder</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Post Marketing:</span> There have been rare reports of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremic</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> associated with concomitant use with the following medications: oxybutinin and imipramine.</p>
<p>See <span class="Bold"><a href="#warnings">WARNINGS</a></span> for the possibility of <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, continuing <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, problems with passing urine and rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. (See <span class="Bold"><a href="#warnings">WARNINGS</a></span>.) In case of overdosage, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. There is no known specific antidote for desmopressin acetate or <span class="Bold">DDAVP Rhinal Tube</span>.</p>
<p>An oral LD<span class="Sub">50</span> has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Central Cranial <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First">This drug is administered into the nose through a soft, flexible plastic rhinal tube which has four graduation marks on it that measure 0.2, 0.15, 0.1 and 0.05 mL. <span class="Bold">DDAVP Rhinal Tube</span> dosage must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover. Patients with <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> and blockage have often responded well to intranasal DDAVP. The usual dosage range in adults is 0.1 to 0.4 mL daily, either as a single dose or divided into two or three doses. Most adults require 0.2 mL daily in two divided doses. The morning and evening doses should be separately adjusted for an adequate diurnal rhythm of water turnover. For children aged 3 months to 12 years, the usual dosage range is 0.05 to 0.3 mL daily, either as a single dose or divided into two doses. About 1/4 to 1/3 of patients can be controlled by a single daily dose of DDAVP administered intranasally. Fluid restriction should be observed. (See <span class="Bold"><a href="#warnings">WARNINGS</a>,</span><span class="Bold"><a href="#Pediatric_Use">PRECAUTIONS, Pediatric Use</a></span> and <span class="Bold"><a href="#precautions_geriatric">Geriatric Use</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See <span class="Bold"><a href="#clinical_pharmacology_human">CLINICAL PHARMACOLOGY, Human Pharmacokinetics</a></span>, <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>, and <span class="Bold"><a href="#precautions_geriatric">PRECAUTIONS, Geriatric Use</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">DDAVP Rhinal Tube</span> is available in a 2.5 mL bottle, packaged with two rhinal tube applicators per carton (NDC 0075-2450-01). Also available in a 5.0 mL pump bottle with spray pump delivering 50 doses of 10 mcg (NDC 0075-2452-01).</p>
<p>Store refrigerated 2 to 8°C (36 to 46°F). When traveling, closed bottles will maintain stability for 3 weeks when stored at controlled room temperature, 20 to 25°C (68 to 77°F).</p>
<p>Keep out of the reach of children.</p>
<p>MILITARY: <span class="Bold">DDAVP Rhinal Tube,</span> 1 × 2.5 mL (NSN 6505-01-145-6338).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br><span class="Bold">sanofi-aventis U.S. LLC</span><br>Bridgewater, NJ 08807<br>A SANOFI COMPANY
						</p>
<p>Revised October 2011<br>©2011 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-12"></a><p></p>
<h1>PATIENT INSTRUCTION GUIDE</h1>
<p class="First"><span class="Bold">DDAVP<span class="Sup">®</span><br>Rhinal Tube<br>(desmopressin acetate)</span></p>
<p><span class="Bold">Ensure that in children administration is under adult supervision in order to control the dose intake.</span></p>
<p>If you accidentally deliver/administer too much of a dose, immediately telephone your doctor or a certified Regional Poison Center for advice. Possible signs of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, continuing <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, problems with passing urine and rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<dl>
<dt class="Bold">1.</dt>
<dd>Pull plastic tag on neck of bottle.</dd>
</dl>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-02.jpg"></div>
<dl>
<dt class="Bold">2.</dt>
<dd>Break security seal and remove plastic cap.</dd>
</dl>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-03.jpg"></div>
<dl>
<dt class="Bold">3.</dt>
<dd>Twist off the small knurled seal from the dropper. <span class="Bold">Use the same seal reversed to prevent subsequent leakage,</span> especially if the bottle is not stored upright.</dd>
</dl>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-04.jpg"></div>
<dl>
<dt class="Bold">4.</dt>
<dd>The drug is administered by a soft, flexible, plastic rhinal tube which has dose marks at 0.2, 0.15, 0.1 and 0.05 mL. Take the arrow-marked part of the tube in one hand and place the fingers of the other hand around the cylindrical part of the closure. Insert the top of the dropper in a downward position into the arrow-marked end of the tube and squeeze the dropper until the solution has reached the desired calibration mark. The dose is measured from the arrow-marked end of the tube to the appropriate calibration. Disconnect the tube from the bottle by withdrawing the bottle quickly downwards. In order to prevent air bubbles from forming in the tube, maintain constant pressure on the dropper. If difficulty is experienced in filling the tube, a diabetic or tuberculin syringe may be used to draw up the dose and load the tube.</dd>
</dl>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-05.jpg"></div>
<dl>
<dt class="Bold">5.</dt>
<dd>Hold the tube with the fingers approximately ¾ inch from the end and insert into a nostril until the tips of the fingers reach the nostril.</dd>
</dl>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-06.jpg"></div>
<dl>
<dt class="Bold">6.</dt>
<dd>Put the other end of the tube into the mouth. Hold the breath, tilt the head back and then blow with a short, strong puff through the tube so that the solution reaches the right place in the nasal cavity. Through this procedure, medication is limited to the nasal cavity and the preparation does not pass down into the throat.<br>In very young patients, it may be necessary for an adult to blow the solution into the child's nose. In such cases, the tube will not need to be put into the nose as far as in the older child or adult. The tube should be placed in the nose gently just far enough so that the solution does not run out. A baby must be held firmly and securely.</dd>
</dl>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-07.jpg"></div>
<dl>
<dt class="Bold">7.</dt>
<dd>
<span class="Bold">After use, reseal dropper tip and close the bottle with the plastic cap.</span> Wash the tube in water and shake thoroughly, until no more water is left. The tube can then be used for the next application.</dd>
</dl>
<p><span class="Bold">IMPORTANT:<br>Replace Knurled Seal</span></p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-08.jpg"></div>
<p>Store refrigerated 2 to 8°C (36 to 46°F). When traveling, closed bottles will maintain stability for 3 weeks when stored at controlled room temperature, 20 to 25°C (68 to 77°F).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br><span class="Bold">sanofi-aventis U.S. LLC</span><br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>Revised October 2011</p>
<p>©2011 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2.5mL Bottle Label</h1>
<p class="First">NDC 0075-2450-01</p>
<p><span class="Bold">DDAVP<span class="Sup">®</span><br>
						Rhinal Tube</span><br><span class="Italics">desmopressin acetate</span></p>
<p><span class="Bold">10</span>µg/<span class="Bold">0.1</span>mL</p>
<p>FOR INTRANASAL<br>
						USE ONLY</p>
<p><span class="Bold">One </span>2.5mL Bottle</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.5mL Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-09.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2.5mL Bottle Carton</h1>
<p class="First">NDC 0075-2450-01</p>
<p><span class="Bold">DDAVP<span class="Sup">®</span><br>
						Rhinal<br>
						Tube</span><br><span class="Italics">desmopressin <br>acetate</span></p>
<p><span class="Bold">10</span>µg/<span class="Bold">0.1</span>mL</p>
<p>FOR INTRANASAL USE ONLY</p>
<p><span class="Bold">One </span>2.5mL Bottle</p>
<p><span class="Bold">sanofi aventis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.5mL Bottle Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95e53e87-2d52-4e37-93ea-89f440938f7a&amp;name=ddavp-10.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DDAVP  		
					RHINAL TUBE</strong><br><span class="contentTableReg">desmopressin acetate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-2450</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">NASAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Desmopressin Acetate</strong> (Desmopressin) </td>
<td class="formItem">Desmopressin Acetate</td>
<td class="formItem">0.1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Chlorobutanol</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-2450-01</td>
<td class="formItem">2.5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017922</td>
<td class="formItem">02/21/1978</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ferring GmbH</td>
<td class="formItem"></td>
<td class="formItem">328609615</td>
<td class="formItem">MANUFACTURE(0075-2450), ANALYSIS(0075-2450), LABEL(0075-2450), PACK(0075-2450)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rechon Life Science AB</td>
<td class="formItem"></td>
<td class="formItem">775207769</td>
<td class="formItem">MANUFACTURE(0075-2450), ANALYSIS(0075-2450), LABEL(0075-2450), PACK(0075-2450)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b1b1e14c-afba-44c1-a384-5aae6a624046</div>
<div>Set id: 95e53e87-2d52-4e37-93ea-89f440938f7a</div>
<div>Version: 7</div>
<div>Effective Time: 20120719</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
